Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.61 - $47.32
Previous CloseN/A
Volume253.49K
Average Volume (3M)1.06M
Market Cap
$2.22B
Enterprise Value$2.93B
Total Cash (Recent Filing)$7.07M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)92.9
Beta2.23
Next Earnings
May 13, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.31
Shares Outstanding77,944,770
10 Day Avg. Volume912,972
30 Day Avg. Volume1,060,279
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.56
Price to Cash Flow (P/CF)25.30
P/FCF Ratio25.30
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda61.92
Forecast
1Y Price Target
$44.71Price Target Upside57.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Veracyte News
PremiumCompany Announcements
Veracyte Inc. Reports Strong 2024 Earnings Amid Challenges
PremiumCompany Announcements
Veracyte Inc. Reports Strong 2024 Financial Performance
---
Bulls Say, Bears Say
Bulls Say
Market Share And AdoptionDecipher has over 65% market share and has driven clinician awareness and adoption with orders increasing across both new and existing accounts.
Revenue GuidanceCore testing revenue guidance came in 3% ($13 million) ahead of consensus and AEBITDA margin guidance was 150 basis points above expectations.
Testing RevenueThe testing business showed continued strength, with Testing revenue growing 24% year-over-year, driven by a 44% increase in Decipher revenue.
Bears Say
Commercial Product ConcernsConcern exists that Veracyte has only two meaningful commercial products.
French Subsidiary UncertaintyThe strategic review of the French subsidiary could potentially delay IVD timelines.
Product Revenue DeclineProduct revenue experienced a year-over-year decline of 18%, impacted by ongoing supply chain issues affecting Prosigna nCounter.
---
Ownership Overview
1.22% Insiders
33.48% Mutual Funds
31.50% Other Institutional Investors
8.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $18.61 and its highest was $47.32 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $2.22B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is May 13, 2025 which is in 38 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Feb 24, 2025. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.113 by -$0.053.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.02.
How many shares outstanding does Veracyte have?
Veracyte has 77,944,770 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.06 in its last earnings report, missing expectations of $0.113. Following the earnings report the stock price went down -14.99%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
---
Veracyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.71 (57.04% Upside)
$44.71 (57.04% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 68.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $460.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.00%
12-Months-Change
Fundamentals
Return on Equity
2.17%
Trailing 12-Months
Asset Growth
17.24%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. is a genomic diagnostics company that leverages advanced genomic technology to improve diagnostic accuracy and outcomes for patients. Operating primarily in the healthcare and biotechnology sectors, the company focuses on developing and commercializing diagnostic tests that aid in the diagnosis of various diseases, particularly in oncology and pulmonology. Veracyte's core products include genomic tests like the Afirma Thyroid FNA Analysis and the Envisia Genomic Classifier, which provide critical genomic insights to guide treatment decisions.
---
VCYT Company Deck
---
VCYT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in revenue growth and market penetration, particularly with the Decipher test. However, there are notable challenges, including a decline in product revenue and potential operational changes in the French subsidiary that could impact future performance and product availability.Read More>---
VCYT Stock 12 Month Forecast
Average Price Target
$44.71
▲(57.04% Upside)
Technical Analysis
Best Analysts Covering VCYT
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+4.68%
reiterated a sell rating 24 days ago
Copying Tejas Savant's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +4.68% per trade.
---